Dyax Corp. (NASDAQ: DYAX) announced today that the Company will participate in the Morgan Stanley Global Healthcare Conference, being held September 9-11, 2013 at the Grand Hyatt in New York City. Gustav Christensen, President and Chief Executive Officer of Dyax, will participate in a fireside chat to discuss the Company’s key value drivers on Wednesday, September 11 at 10:00 AM (ET).
This presentation will be webcast live and may be accessed by visiting the Investor Relations section of the company website at
. The webcast will also be available on the Dyax website for a limited period of time following the conference.
Dyax is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs. The Company's key value drivers are the KALBITOR
(ecallantide) business, DX-2930 and the Licensing and Funded Research Program (LFRP).
Dyax developed KALBITOR on its own and, since February 2010, has been selling it in the United States for the treatment of acute attacks of HAE in patients 16 years of age and older. Outside the United States, the Company has established partnerships to obtain regulatory approval and commercialize KALBITOR in certain markets and is evaluating opportunities in others.
The Company is developing products to expand its angioedema portfolio, including a therapeutic candidate, DX-2930, for the prophylactic treatment of HAE and a diagnostic test to identify plasma kallikrein-mediated disorders. In August 2013, Dyax began a Phase 1 clinical study evaluating the safety and tolerability of single subcutaneous administration of DX-2930 in healthy subjects.
KALBITOR and DX-2930 were identified using Dyax's patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through the LFRP. This program has provided the Company a portfolio of product candidates being developed by its licensees, which currently includes 13 revenue generating product candidates in various stages of clinical development, including three in Phase 3 trials.